An American doctor who was exposed to the Ebola virus while volunteering in Sierra Leone was admitted Sunday to a hospital at the National Institutes of Health near the nation's capital.
The Nebraska hospital that treated an American aid worker infected with Ebola has fired two workers accused of violating the man's privacy by looking at his medical file.
Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.
Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move allows Chiltern to offer integrated services throughout the Asia-Pacific region and strengthens in particular Chiltern's oncology and anti-infective offerings.
Allergan announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME).
The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $75 million in stock on the privately held Lumara, which makes Makena, a treatment designed to reduce the risk of premature birth.
Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
Alimera Sciences and pSivida said Friday the FDA approved their eye disease implant Iluvien. Iluvien is an implant delivered by injection that is intended to treat diabetic macular edema, a condition that can cause blurred vision and blindness.
Pfizer announced that it has completed its acquisition of pharmaceutical development company, InnoPharma, Inc., and Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American-branded generics pharmaceutical presence.
Chemists have gained fresh insights into how a disease-causing enzyme makes changes to proteins and how it can be stopped. They hope their findings will help to design drugs that could target the enzyme, known as NMT, and potentially lead to new treatments for cancer and inflammatory conditions.
The FDA cleared Humira as a treatment for moderate to severe Crohn's disease in children ages six and older when those children haven't been helped by other treatments, AbbVie said. Humira can be administered at home, unlike similar drugs used to treat the condition.
Access to potentially life-extending cancer drugs varies significantly in different regions of the world, two new studies show. Researchers say the results demonstrate the need for better collaboration between doctors and health authorities on an international scale, to ensure patients have access to the best treatments.
Akorn, Inc. has broken ground on a project that will add 40,000 square feet to its plant. The company recently bought a neighboring property to accommodate the expansion, which includes remodeling and modernizing equipment as part of an $18 million effort to increase production.
The World Health Organization says there should be thousands of doses of experimental Ebola vaccines available in the coming months and they could eventually be given to health care workers and other people who have had contact with the sick.
Pacira Pharmaceuticals Inc. said Thursday that it received a warning letter from regulators about marketing for an injectable drug that numbs post-surgical pain that the letter says is misleading.